Today: 29 April 2026
Browse Category

NASDAQ:CMG 12 October 2025 - 22 January 2026

Chipotle Stock Tumbles on Third Forecast Cut — Can the Burrito Chain Bounce Back?

Chipotle Stock Craters After Tepid Q3 Earnings – What’s Next for CMG?

Chipotle shares plunged 18% pre-market Oct. 30 after management cut its 2025 same-store sales forecast to a low-single-digit decline, citing persistent macroeconomic pressures. Q3 revenue rose 7.5% to $3.0 billion, but same-store sales grew just 0.3% as customer traffic fell for the third straight quarter. Chipotle opened 84 new restaurants and repurchased $686.5 million in stock. The stock is down 34% year-to-date.
30 October 2025
···
Chipotle Stock Tumbles on Third Forecast Cut — Can the Burrito Chain Bounce Back?

Chipotle Stock Tumbles on Third Forecast Cut — Can the Burrito Chain Bounce Back?

Chipotle shares closed at $40.40 on Oct. 29, down 31% from early 2025. The company reported Q3 adjusted EPS of $0.29 on $3.00 billion revenue, missing sales estimates and posting just 0.3% same-store growth. Management cut its 2025 outlook for the third time, now expecting same-store sales to decline. The stock fell 1–2% after hours following the update.
29 October 2025
··
Mexican Dining Crisis: Beloved Chains File Bankruptcy and Close Doors as Industry Hits Breaking Point

Mexican Dining Crisis: Beloved Chains File Bankruptcy and Close Doors as Industry Hits Breaking Point

Abuelo’s Mexican Food Embassy filed for Chapter 11 and closed 24 locations, joining El Burro Loco, On The Border, Rubio’s Coastal Grill, and Tijuana Flats in a wave of bankruptcies among U.S. Mexican restaurant chains since 2024. Industry reports cite falling sales, rising costs, and changing consumer habits as key factors. Chipotle’s stock fell 13% in July 2025 after weak sales. Restaurant menu prices rose nearly 4% year-over-year by August 2025.
12 October 2025
··

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 3:00 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop